Meanwhile, data from a double blinded placebo controlled clinical study indicates that INT-747 improves insulin sensitivity (http://www.interceptpharma.com/) in nonalcoholic fatty liver disease (NAFLD) patients with type II diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.